As earnings approach NASDAQ:KALA is taking a very bullish trajectory and seemingly some positioning is taking place. Currently the 200 &100 day MA's are converging and will hopefully avoid a bearish cross , if the price can break above we believe it to a good entry point.
AVERAGE ANALYSTS PRICE TARGET $19.57
AVERAGE ANALYSTS RECOMMENDATION buy
P/E...
$KALA $LABU $LABD
This is my first published idea on Tradingview. I play biotech and pdufa run up and data releases. KALA has a pdufa aug 15th, based on the chart it looks to be heading into a bullish run into possible FDA approval.
I made three resistance points to watch out based on the 50 and 200 moving averages as well as prior resistance points. GLTA!!!...
KALA focused on the development and commercialization of therapeutics using proprietary AMPPLIFY mucus-penetrating particle, or MPP, drug delivery technology, with an initial focus on the treatment of eye diseases
INVELTYS - approved by FDA on August 22, 2018. US launch in January 2019
KPI121 0.25% - on PH3 (Third trail on-going), Top line results expected in Q4...
Please refer to chart for further information:
1) Initial I.P.O. lock out is done (6 months), then selling
2) Over 1 million shares bought by INSIDERS (blue lines)
3) Earnings scheduled for before trading on 3/16/2018
4) $21 plus looks easy for Price Action to do... next month or too
Looks like a strong buy to me at this time. Please do own research if you are...
I bought 1000 shares of KALA
Watching: $13.51 - $13.68
Then, I can Relax!
Target = $14.32 for a "Hold."
I would like to Double my Money, on this Stock. :-)
KALA, Create buy limit order and Other Cancels Other order for target and stop prices. Still learning
Buy order: 10.80
Price Target: 16.00
Stop Loss: 9.75
Kala Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program. The Company has completed two Phase III clinical trials for KPI-121 1% . The KPI-121 0.25% is the Company’s product candidate for temporary relief of signs and symptoms of dry eye disease. KPI-121 1% is the twice-a-day product candidate for treatment of post-operative inflammation and pain following ocular surgery. MPP rTKI Program is therapies for retinal diseases that should be injected directly into the patient's eye, often at monthly intervals.
This website uses cookies to ensure you get the best experience on our website. To learn more about cookies, including how to control cookies, please read our Cookies Policy.
KALA
